Details for Patent: 8,754,109
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,754,109 protect, and when does it expire?
Patent 8,754,109 protects ESBRIET and is included in two NDAs.
This patent has forty patent family members in thirty countries.
Summary for Patent: 8,754,109
Title: | Pirfenidone therapy and inducers of cytochrome P450 |
Abstract: | The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. |
Inventor(s): | Bradford; Williamson Z. (Ross, CA), Szwarcberg; Javier (San Francisco, CA) |
Assignee: | Intermune, Inc. (Brisbane, CA) |
Application Number: | 13/513,472 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,754,109 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,754,109
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER | See Plans and Pricing | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY | See Plans and Pricing | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY | See Plans and Pricing | ||||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,754,109
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
10250378 | Mar 3, 2010 | |
Canada | 2710014 | Oct 8, 2010 |
PCT Information | |||
PCT Filed | December 03, 2010 | PCT Application Number: | PCT/US2010/058936 |
PCT Publication Date: | June 09, 2011 | PCT Publication Number: | WO2011/069089 |
International Family Members for US Patent 8,754,109
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 523197 | See Plans and Pricing | |||
Australia | 2010212488 | See Plans and Pricing | |||
Brazil | 112012013155 | See Plans and Pricing | |||
Canada | 2710014 | See Plans and Pricing | |||
Chile | 2012000952 | See Plans and Pricing | |||
Cyprus | 1112075 | See Plans and Pricing | |||
Denmark | 2308491 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |